financetom
Business
financetom
/
Business
/
Update: MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Fiscal 2025 Outlook Raised -- Shares Jump After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: MongoDB Q3 Non-GAAP Earnings, Revenue Increase; Fiscal 2025 Outlook Raised -- Shares Jump After Hours
Dec 9, 2024 2:12 PM

04:53 PM EST, 12/09/2024 (MT Newswires) -- (Updates with COO and CFO Michael Gordon stepping down in the seventh paragraph and the latest stock move in the last paragraph.)

MongoDB ( MDB ) reported Q3 non-GAAP earnings late Monday of $1.16 per diluted share, up from $0.96 a year earlier.

Analysts polled by FactSet expected $0.68.

Revenue for the quarter ended Oct. 31 was $529.4 million, up from $432.9 million a year earlier.

Analysts surveyed by FactSet expected $497.2 million.

The company said it expects Q4 non-GAAP EPS between $0.62 and $0.65 and revenue between $515 million and $519 million. Analysts polled by FactSet expect $0.56 and $507.8 million, respectively.

The company expects fiscal 2025 non-GAAP EPS between $3.01 and $3.03 and revenue between $1.97 billion and $1.98 billion. The company previously expected non-GAAP EPS of $2.33 to $2.47 and revenue of $1.92 billion to $1.93 billion. Analysts surveyed by FactSet expect non-GAAP EPS of $2.43 and revenue of $1.94 billion.

MongoDB ( MDB ) also said Chief Operating Officer and Chief Financial Officer Michael Gordon will be stepping down on Jan. 31, 2025. The company said it has launched a search process for a new CFO, and Serge Tanjga, senior vice president of finance, will be interim CFO starting Feb. 1 if a permanent successor hasn't been named by then.

Shares of the company jumped 8.5% in recent after-hours activity.

Price: 380.02, Change: +29.89, Percent Change: +8.54

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved